Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy

[1]  E. Osinaga,et al.  Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives , 2022, Cancers.

[2]  A. Tafreshi,et al.  Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  H. Yao,et al.  Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study , 2021, EBioMedicine.

[4]  E. Schaafsma,et al.  Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy , 2021, British Journal of Cancer.

[5]  Cun-Yu Wang,et al.  CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. , 2021, Cell stem cell.

[6]  A. Tafreshi,et al.  Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Jonasch,et al.  High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  C. Hammer,et al.  Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion , 2021, Nature Reviews Cancer.

[9]  H. Yao,et al.  Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics–Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer , 2020, JAMA network open.

[10]  M. Netea,et al.  Innate Immune Training of Granulopoiesis Promotes Anti-tumor Activity , 2020, Cell.

[11]  M. Kudo,et al.  Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib , 2020, JAMA oncology.

[12]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[13]  H. Yao,et al.  Association of Immune Checkpoint Inhibitor Therapy With Survival in Patients With Cancers With MUC16 Variants , 2020, JAMA network open.

[14]  Chenqi Xu,et al.  Immune checkpoint signaling and cancer immunotherapy , 2020, Cell Research.

[15]  H. Yao,et al.  Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer , 2020, JAMA network open.

[16]  Ming Xu,et al.  Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer , 2020, Journal of Translational Medicine.

[17]  Xuefei Huang,et al.  Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy. , 2020, Seminars in immunology.

[18]  Takla Griss,et al.  Metabolic Profiling Using Stable Isotope Tracing Reveals Distinct Patterns of Glucose Utilization by Physiologically Activated CD8+ T Cells. , 2019, Immunity.

[19]  D. Jäger,et al.  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Ruppin,et al.  Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1. , 2019, JAMA oncology.

[21]  Junkai Wang,et al.  Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). , 2019, Journal of the National Cancer Institute.

[22]  R. Medzhitov,et al.  Harnessing innate immunity in cancer therapy , 2019, Nature.

[23]  Betty Y. S. Kim,et al.  Phagocytosis checkpoints as new targets for cancer immunotherapy , 2019, Nature Reviews Cancer.

[24]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[25]  R. Deberardinis,et al.  Mechanisms and Implications of Metabolic Heterogeneity in Cancer. , 2019, Cell metabolism.

[26]  Jason W Locasale,et al.  Metabolic landscape of the tumor microenvironment at single cell resolution , 2019, Nature Communications.

[27]  L. Shevde,et al.  The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.

[28]  S. Matosevic,et al.  Immunometabolic Dysfunction of Natural Killer Cells Mediated by the Hypoxia-CD73 Axis in Solid Tumors , 2019, Front. Mol. Biosci..

[29]  H. Yao,et al.  Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer , 2019, JAMA network open.

[30]  S. Coffelt,et al.  γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer , 2019, Nature Reviews Cancer.

[31]  C. Graham,et al.  DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes , 2019, Journal of Immunotherapy for Cancer.

[32]  Chao Yang,et al.  The role of necroptosis in cancer biology and therapy , 2019, Molecular Cancer.

[33]  A. Sreekumar,et al.  Measurement of methylated metabolites using Liquid Chromatography-Mass Spectrometry and its biological application. , 2019, Analytical methods : advancing methods and applications.

[34]  Shasha Liu,et al.  Fates of CD8+ T cells in Tumor Microenvironment , 2018, Computational and structural biotechnology journal.

[35]  M. Berger,et al.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy , 2018, Science.

[36]  J. Taube,et al.  Implications of the tumor immune microenvironment for staging and therapeutics , 2018, Modern Pathology.

[37]  I. Amelio,et al.  The hypoxic tumour microenvironment , 2018, Oncogenesis.

[38]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[39]  S. Terry,et al.  Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity , 2017, Front. Immunol..

[40]  R. Farré,et al.  Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea , 2017, European Respiratory Journal.

[41]  Karin Milde-Langosch,et al.  Role of protein glycosylation in cancer metastasis. , 2017, Seminars in cancer biology.

[42]  S. Gettinger,et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.

[43]  D. Elliott,et al.  Hallmarks of glycosylation in cancer , 2016, Oncotarget.

[44]  Abdel Kareem Azab,et al.  The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.

[45]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[46]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[47]  Y. Chien,et al.  γδ T cells: first line of defense and beyond. , 2014, Annual review of immunology.

[48]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[49]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[50]  A. Hill,et al.  Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase , 2011, Breast Cancer Research.

[51]  W. Wheaton,et al.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity , 2010, Proceedings of the National Academy of Sciences.

[52]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[53]  P. Casey,et al.  Activation of Rap1 promotes prostate cancer metastasis. , 2009, Cancer research.

[54]  C. Burant,et al.  Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. , 2006, Cancer research.

[55]  L. Wilkinson.  Immunity , 1891, The Lancet.

[56]  J. Downward.  Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.